30 Day Trial

Novo Nordisk Is Evaluating a Once-Yearly Semaglutide Implant. Why That Matters for the Drinks Industry.

Novo Nordisk has agreed to conduct a non-exclusive internal evaluation of NPM-139, a miniature subcutaneous semaglutide implant developed by California-based biopharmaceutical company Vivani Medical, designed for once- or twice-yearly chronic weight management dosing. The agreement was announced by Vivani Medical via SEC Form 8-K filing and GlobeNewswire press release on 7 July 2026. No financial terms were disclosed and no exclusivity provisions apply – Novo Nordisk is being granted access to evaluate the technology without any commitment to license, acquire, or develop it further. Vivani retains full freedom to approach other partners with the same asset.

Refine Drinks · Member Content
This piece is for Refine Drinks members.
Refine Drinks covers what matters for commercial and strategy leaders in drinks - results, M&A, and market shifts read for what they mean for decisions you're actually making.
Category Intelligence
Where each drinks category is heading - and what it means for brand and commercial decisions.
Company Intelligence
Financial results and strategic moves - read for what they mean to the brands around them.
Market Intelligence
Geographic developments with a specific read on what to do with the information.
How To
Practical guides for commercial and strategy teams - built on primary data, not general advice.
£199
per year - full access from day one
Become a member →
Already a member? Sign in here.